Car driving on road from above
NEWS FROM ALNYLAM

Here you can find the latest press releases from Alnylam.

PDF icon
Download PDF ›240.73 KB
PRESS RELEASE
May 18, 2022
Alnylam launches third RNAi therapeutic approved in Canada240.73 KB
PDF icon
Download PDF ›193.57 KB
PRESS RELEASE
March 17, 2021
Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran)193.57 KB
PDF icon
Download PDF ›80.48 KB
PRESS RELEASE
July 23, 2019
Alnylam launches the first ever RNAi therapeutic approved in Canada80.48 KB
PDF icon
Download PDF ›1.29 MB
PRESS RELEASE
May 15, 2019
Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time1.29 MB
PDF icon
Download PDF ›269.41 KB
PRESS RELEASE
November 26, 2018
Alnylam Pharmaceuticals: Bringing groundbreaking gene silencing therapies to Ontario.269.41 KB
PDF icon
Download PDF ›95.3 KB
PRESS RELEASE
September 24, 2018
Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy95.3 KB

GET IN TOUCH

Questions, concerns, or comments about this content? We encourage you to reach out to our team.

Contact us ›

OTHER INQUIRIES

Media: media@alnylam.com

Investor Relations: investors@alnylam.com

General: info@alnylam.ca